CEA

Carcinoembryonic Antigen

Tumor Markers

What is Carcinoembryonic Antigen?

Carcinoembryonic antigen (CEA) is a glycoprotein involved in cell adhesion that was first identified in 1965 in extracts of human colon carcinoma tissue and fetal gut. It belongs to the immunoglobulin superfamily and is anchored to the cell membrane via a glycosylphosphatidylinositol (GPI) linkage. During fetal development, CEA is produced in gastrointestinal tissue and its production normally decreases after birth, with low levels present in the blood of healthy adults.

CEA is the most widely used tumor marker for colorectal cancer (CRC). Its primary clinical utility lies in monitoring for recurrence after curative surgery, assessing response to chemotherapy in metastatic disease, and aiding prognostic stratification. Elevated preoperative CEA is an independent adverse prognostic factor in colorectal cancer. CEA is not suitable for screening because it lacks sensitivity for early-stage disease and is elevated in many benign conditions and other malignancies. Smoking is a well-established cause of mildly elevated CEA in the absence of malignancy.

Why It Matters

CEA is the standard serum marker for colorectal cancer surveillance. A rising CEA after curative surgery is often the earliest sign of recurrence, preceding imaging findings by several months, and may prompt earlier intervention with potentially curative salvage surgery. In metastatic colorectal cancer, serial CEA tracks chemotherapy response. Preoperative CEA >5 ng/mL is an adverse prognostic factor. While CEA is elevated in multiple cancer types, its clinical validation is strongest for colorectal cancer.

Normal Reference Ranges

Group	Range	Unit
Non-smokers	0–3.0	ng/mL
Smokers	0–5.0	ng/mL

Reference ranges may vary by laboratory. Always compare results to the ranges provided by your testing facility.

What High CEA Levels Mean

Common Causes

Colorectal cancer (most validated use)
Smoking (mild elevations up to 5–10 ng/mL)
Inflammatory bowel disease (Crohn's, ulcerative colitis)
Pancreatitis and pancreatic cancer
Gastric, breast, and lung cancers
Liver cirrhosis and hepatitis
Peptic ulcer disease
Hypothyroidism
Cholecystitis

Possible Symptoms

Change in bowel habits
Rectal bleeding or blood in stool
Unexplained weight loss
Abdominal pain or cramping
Fatigue and weakness
Iron deficiency anemia

What to do: In known colorectal cancer patients, a rising CEA warrants imaging (CT of chest, abdomen, pelvis) to identify the site of recurrence. If CEA rises postoperatively but imaging is negative, PET/CT or colonoscopy may be considered. For initial elevations without a cancer diagnosis, investigate benign causes (smoking, inflammatory conditions, liver disease) and consider repeat testing in 4–8 weeks. Persistent unexplained elevations should prompt further investigation including colonoscopy.

What Low CEA Levels Mean

Common Causes

Normal physiological state
Successful surgical resection or treatment of cancer

Possible Symptoms

No symptoms associated with low CEA

What to do: Low CEA is normal and expected. After colorectal cancer surgery, normalization of CEA (within 4–6 weeks postoperatively) is a favorable prognostic indicator. However, some colorectal cancers do not produce CEA, so a normal level does not guarantee the absence of disease. Continued surveillance with imaging and colonoscopy is still necessary.

When Is CEA Testing Recommended?

Preoperative staging and prognosis in colorectal cancer
Post-surgical surveillance for colorectal cancer recurrence (every 3–6 months for 2 years, then every 6 months for 3 more years)
Monitoring response to chemotherapy in metastatic colorectal cancer
Evaluating unexplained liver metastases of unknown primary

Frequently Asked Questions

Not necessarily. CEA can be elevated in many benign conditions including smoking, inflammatory bowel disease, liver disease, and hypothyroidism. Mild elevations (3–10 ng/mL) are more often benign, while very high levels (>20 ng/mL) are more concerning for malignancy. Clinical context, imaging, and often colonoscopy are needed to determine the cause.

ASCO and NCCN guidelines recommend measuring CEA every 3–6 months for the first 2 years after surgery, then every 6 months for years 3–5. CEA monitoring is recommended for stage II and III patients who would be candidates for further treatment if recurrence is detected.

No. CEA is not sensitive enough for early-stage detection—it is elevated in only about 30–40% of stage I–II colorectal cancers. Colonoscopy remains the gold standard for early detection and screening. CEA is most useful for recurrence surveillance and monitoring advanced disease.

Related Biomarkers

CA 19-9Cancer Antigen 19-9 CA-125Cancer Antigen 125

Want your CEA levels analyzed?

Upload your lab results for an instant AI-powered breakdown of all your biomarkers.

Upload Lab Results →

Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Reference ranges may vary between laboratories. Always consult your healthcare provider for interpretation of your specific test results.